Rare clotting events associated with ChAdOx1 vaccine
The ChAdOx1 COVID-19 vaccine is associated with a small increased risk for idiopathic thrombocytopenic purpura (ITP), according to a study published online June 9 in Nature Medicine.
Colin R. Simpson, Ph.D., from the Victoria University of Wellington in New Zealand, and colleagues used a nested incident-matched case-control study and confirmatory self-controlled case series (SCCS) analysis to estimate associations between exposure to the first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse events.
The researchers identified an association between ChAdOx1 vaccination and ITP zero to 27 days after vaccination (adjusted rate ratio [aRR], 5.77; 95 percent confidence interval [CI], 2.41 to 13.83), with an estimated incidence of 1.13 per 100,000 doses; in the SCCS analysis, this finding was found to be unlikely due to bias (RR, 1.98; 95 percent CI, 1.29 to 3.02). An increased risk for arterial thromboembolic events was also seen at zero to 27 days after vaccination (aRR, 1.22; 95 percent CI, 1.12 to 1.34), with an SCCS RR of 0.97 (95 percent CI, 0.93 to 1.02). There were no positive associations seen for BNT162b2 with thrombocytopenic, thromboembolic, or hemorrhagic events.
“Reassuringly, we did not identify any overall increased risk of ITP, clotting, and bleeding events in those receiving the Pfizer-BioNTech mRNA vaccine,” Simpson said in a statement. “We are now planning to update our analysis as the vaccine program is being extended to younger, healthier individuals and as new vaccines are becoming available.”
COVID-19 vaccine linked to low platelet count, nationwide study suggests
Rare clotting events associated with ChAdOx1 vaccine (2021, June 18)
retrieved 19 June 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.